Extra criterial antiphospholipid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data)

The role of antiphospholipid antibodies (aPL), which are not included in the classification criteria, in antiphospholipid syndrome (APS) and
systemic lupus erythematosus (SLE) is not well understood.
Objective: to determine the frequency of detection of IgG antibodies to domain 1 of β₂-glycoprotein 1 (IgG-aβ₂GP₁-D₁), IgA antibodies
to cardiolipin (aCL) and IgA antibodies to β₂-glycoprotein 1 (IgA-a β₂GP₁) in patients with primary APS and APS in combination with
SLE.
Patients and methods. The study included 63 patients in whom IgG/IgM-aCL and IgG/IgM-aβ₂GP₁ were detected by enzyme-linked
immunosorbent assay (ELISA) and IgG/IgM/IgA-aCL, IgG/IgM/IgA-aβ₂GP₁ and IgG-aβ₂GP₁-D₁ by chemiluminescence analysis (CLA).
Results and discussion. The detection rate of IgG-aβ₂GP₁-D₁ was 76%, IgA-aCL – 56%, IgA-aβ₂GP₁ – 48%. Isolated positivity for IgA-aCL,
IgA-aβ₂GP₁, IgG-aβ₂GP₁-D1 was not observed. The presence of IgA-aCL, IgA-aβ₂GP₁, IgG-aβ₂GP₁-D₁ was associated with high positivity for
IgG/IgM-aCL and IgG/IgM-aβ₂GP₁. There was a statistically significant relationship between IgA-aCL/IgA-aβ₂GP₁ and the standard aPL
profile, as well as IgG-aβ₂GP₁-D₁, IgG-aCL and IgG-aβ₂GP₁.
Conclusion. A high detection rate of IgG-aβ2GP₁-D₁, IgA-aCL, IgA-aβ₂GP₁ was found in patients with APS. A statistically significant relationship
was found between IgA-aCL/IgA-aβ₂GP₁ and the standard aPL profile, as well as IgG-aβ₂GP₁-D₁ with IgG-aCL and IgG-aβ₂GP₁.

1. Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (lecture). Nauchno-prakticheskaya revmatologiya. 2014;52(1):56-71. (In Russ.).

2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753. x

3. Насонов ЕЛ. Антифосфолипидный синдром. Монография. Москва: Литерра; 2004. 36 с.

4. Tincani A, Filippini M, Scarsi M, et al. European attempts for the standardisation of the antiphospholipid antibodies. Lupus. 2009 Sep;18(10):913-9. doi: 10.1177/0961 203309106919.

5. Devreese KM, Pierangeli SS, de Laat B, et al. Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost. 2014 May;12(5):792-5. doi: 10.1111/jth.12537

6. Mahler M, Albesa R, Zohoury N, et al. Autoantibodies to domain 1 of β2 glycoprotein I determined using a novel chemilumines-cence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome. Lupus. 2016 Jul; 25(8):911-6. doi: 10.1177/0961203316640366

7. McNeeley PA, Dlott JS, Furie RA, et al. Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost. 2001 Aug;86(2):590-5.

8. De Laat B, Derksen RH, van Lummel M, et al. Pathogenic anti-beta2 glycoprotein I antibodies recognize domain I of beta-2 glycoprotein I only after a conformational change. Blood. 2006 Mar 1;107(5):1916-24. doi: 10.1182/blood-2005-05-1943

9. Giannakopoulos B, Krillis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013 Mar 14;368(11):1033-44. doi: 10.1056/NEJMra1112830.

10. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005 Oct 1;106(7):2340-6. doi: 10.1182/blood-2005-03-1319. Epub 2005 Jun 14.

11. De Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005 Feb 15;105(4):1540-5. doi: 10.1182/blood-2004-09-3387. Epub 2004 Oct 26.

12. Chighizola CB, Gerosa M, Meroni PL. New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep. 2014 Feb;16(2):402. doi: 10.1007/s11926-013-0402-7

13. Meneghel L, Ruffatti A, Gavasso S, et al. Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clin Chim Acta. 2015 Jun 15;446:201-5. doi: 10.1016/j.cca.2015.04.033. Epub 2015 Apr 30.

14. De Craemer AS, Musial J, Devreese KM. Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost. 2016 Sep;14(9):1779-87. doi: 10.1111/jth.13389

15. Bertolaccini ML, Sanna G. The Clinical Relevance of Noncriteria Antiphospholipid Antibodies. Semin Thromb Hemost. 2018 Jul 3;44(5):453-7. doi: 10.1055/s-0037-1601328

16. Meijide H, Sciascia S, Sanna G, et al. The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev. 2013 Jan;12(3):421-5. doi: 10.1016/j.autrev.2012.08.002

17. Lakos G, Kiss E, Regёczy N, et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol. 1999 Sep;117(3):574-9. doi: 10.1046/j.1365-2249.1999.01007.x

18. Diri E, Cucurull E, Gharavi AE, et al. Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Lupus. 1999;8(4):263-8. doi: 10.1191/096120399678847812

19. Liu T, Gu J, Wan L, et al. «Non-criteria» antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort. Arthritis Res Ther. 2020 Feb 21;22(1):33. doi: 10.1186/s13075-020-2131-4

20. Martinez-Flores JA, Serrano M, Perez D, et al. Detection of circulating immune complexes of human IgA and beta 2 glycoprotein I in patients with antiphospholipid syndrome symptomatology. J Immunol Methods. 2015 Jul;422:51-8. doi: 10.1016/j.jim.2015.04.002

21. Pericleous C, Ferreira I, Borghi O, et al. Measuring IgA anti-β2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. PLoS One. 2016 Jun 2; 11(6):e0156407. doi: 10.1371/journal.pone.0156407

22. Lee RM, Branch DW, Silver RM. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol. 2001 Sep;185(3):748-53. doi: 10.1067/mob.2001.117659

23. Tedesco F, Borghi MO, Gerosa M, et al. Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. Front Immunol. 2018 Jun 19;9:1388. doi: 10.3389/fimmu.2018.01388.eCollection 2018.

24. De Sousa-Pereira P, Woof JM. IgA: Structure, Function, and Developability. Antibodies (Basel). 2019 Dec 5;8(4):57. doi: 10.3390/antib8040057

25. Mulla MJ, Brosens JJ, Chamley LW, et al. Antiphospholipid antibodies induce a proinflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol. 2009 Aug;62(2):96-111. doi: 10.1111/j.1600-0897.2009.00717.x

26. Morales JM, Serrano M, Martinez-Flores JA, et al. Antiphospholipid Syndrome and Renal Allograft Thrombosis. Transplantation. 2019 Mar;103(3):481-6. doi: 10.1097/TP.0000000000002510

27. Meroni PL, Chighizola CB, Rovelli F, Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther. 2014;16(2):209. doi: 10.1186/ar4549

28. Nasonov EL, Beketova TV, Reshetnyak TM, et al. Coronavirus disease 2019 (COVID-19) and immuno-inflammatory rheumatic diseases: at the intersection of thromboinflammation and autoimmunity problems. Nauchno-prakticheskaya revmatologiya. 2020; 58(4):353-67. (In Russ.).

29. Cabrera-Marante O, Rodriguez de Frias E, Serrano M, et al. The Weight of IgA Anti-β2 glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome. Int J Mol Sci. 2020 Nov 26;21(23):8972. doi: 10.3390/ijms21238972

30. Sikara MP, Routsias JG, Samiotaki M, et al.{beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): Implications for the pathogenesis of antiphospholipid syndrome. Blood. 2010 Jan 21;115(3):713-23. doi: 10.1182/blood-2009-03-206367. Epub 2009 Oct 5.

31. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575.Epub 2020 Apr 8.

32. Devreese KMJ, Linskens EA, Benoit D, Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: Arelevant observation? J Thromb Haemost. 2020 Sep;18(9): 2191-201. doi: 10.1111/jth.14994. Epub 2020 Jul 23.

33. Reshetnyak TM, Chel'dieva FA, Lila AM, Nasonov EL. Hemostatic disorders, thrombosis, antiphospholipid antibodies in patients with COVID-19. Consilium Medicum. 2021; 2(1):35-42. (In Russ.).